Maintaining K+ balance on the low-Na+, high-K+ diet

Hyperkalemia: pathophysiology, risk factors and consequences

There have been significant recent advances in our understanding of the mechanisms that maintain potassium homoeostasis and the clinical consequences of hyperkalemia. In this article we discuss these advances within a concise review of the pathophysiology, risk factors and consequences of hyperkalemia. We highlight aspects that are of particular relevance for clinical practice. Hyperkalemia occurs when renal potassium excretion is limited by reductions in glomerular filtration rate, tubular flow, distal sodium delivery or the expression of aldosterone-sensitive ion transporters in the distal nephron. Accordingly, the major risk factors for hyperkalemia are renal failure, diabetes mellitus, adrenal disease and the use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers or potassium-sparing diuretics. Hyperkalemia is associated with an increased risk of death, and this is only in part explicable by hyperkalemia-induced cardiac arrhythmia. In addition to its well-established effects on cardiac excitability, hyperkalemia could also contribute to peripheral neuropathy and cause renal tubular acidosis. Hyperkalemia-or the fear of hyperkalemia-contributes to the underprescription of potentially beneficial medications, particularly in heart failure. The newer potassium binders could play a role in attempts to minimize reduced prescribing of renin-angiotensin inhibitors and mineraolocorticoid antagonists in this context.

Furosemide reduces BK-αβ4-mediated K+ secretion in mice on an alkaline high-K+ diet

Special high-K diets have cardioprotective effects and are often warranted in conjunction with diuretics such as furosemide for treating hypertension. However, it is not understood how a high-K diet (HK) influences the actions of diuretics on renal K⁺ handling. Furosemide acidifies the urine by increasing acid secretion via the Na⁺-H⁺ exchanger 3 (NHE3) in TAL and vacuolar H⁺-ATPase (V-ATPase) in the distal nephron. We previously found that an alkaline urine is required for large conductance Ca²⁺-activated K⁺ (BK)-αβ4-mediated K⁺ secretion in mice on HK. We therefore hypothesized that furosemide could reduce BK-αβ4-mediated K⁺ secretion by acidifying the urine. Treating with furosemide (drinking water) for 11 days led to decreased urine pH in both wild-type (WT) and BK-β4-knockout mice (BK-β4-KO) with increased V-ATPase expression and elevated plasma aldosterone levels. However, furosemide decreased renal K⁺ clearance and elevated plasma [K⁺] in WT but not BK-β4-KO. Western blotting and immunofluorescence staining showed that furosemide treatment decreased cortical expression of BK-β4 and reduced apical localization of BK-α in connecting tubules. Addition of the carbonic anhydrase inhibitor, acetazolamide, to furosemide water restored urine pH along with renal K⁺ clearance and plasma [K⁺] to control levels. Acetazolamide plus furosemide also restored the cortical expression of BK-β4 and BK-α in connecting tubules. These results indicate that in mice adapted to HK, furosemide reduces BK-αβ4-mediated K⁺ secretion by acidifying the urine.

Loop diuretics are K+-sparing in the presence of a low-Na+, high-K+ diet

Under most conditions, loop diuretics are K⁺-wasting, requiring potassium supplementation. In this issue, Wang and colleagues demonstrate that in mice fed a low-Na⁺, high-K⁺ diet, loop diuretics, in contrast, are K⁺-sparing. This observation suggests that possible elevations in plasma K⁺ should be monitored when using a loop diuretic with a low-Na⁺, high-K⁺ diet, particularly when in combination with a potassium supplement.

The therapeutic potential of targeting the Kir1.1 (renal outer medullary K+) channel

K_ir1.1 (renal outer medullary K⁺) channels are potassium channels expressed almost exclusively in the kidney and play a role in the body's electrolyte and water balance. Potassium efflux through K_ir1.1 compliments the role of transporters and sodium channels that are the targets of known diuretics. Consequently, loss-of-function mutations in men and rodents are associated with salt wasting and low blood pressure. On this basis, K_ir1.1 inhibitors may have value in the treatment of hypertension and heart failure. Efforts to develop small molecule K_ir1.1 inhibitors produced MK-7145, which entered into clinical trials. The present manuscript describes the structure-activity relationships associated with this scaffold alongside other preclinical K_ir1.1 blockers.

Net K+ secretion in the thick ascending limb of mice on a low-Na, high-K diet

Because of its cardio-protective effects, a low-Na, high-K diet (LNaHK) is often warranted in conjunction with diuretics to treat hypertensive patients. However, it is necessary to understand the renal handling of such diets in order to choose the best diuretic. Wild-type (WT) or Renal Outer Medullary K channel (ROMK) knockout mice (KO) were given a regular (CTRL), LNaHK, or high-K diet (HK) for 4-7 days. On LNaHK, mice treated with either IP furosemide for 12 hrs, or given furosemide in drinking water for 7 days, exhibited decreased K clearance. We used free-flow micropuncture to measure the [K⁺] in the early distal tubule (EDT [K⁺]) before and after furosemide treatment. Furosemide increased the EDT [K⁺] in WT on CTRL but decreased that in WT on LNaHK. Furosemide did not affect the EDT [K⁺] of KO on LNaHK or WT on HK. Furosemide-sensitive Na⁺ excretion was significantly greater in mice on LNaHK than those on CTRL or HK. Patch clamp analysis of split-open TALs revealed that 70-pS ROMK exhibited a higher open probability (Po) but similar density in mice on LNaHK, compared with CTRL. No difference was found in the density or Po of the 30 pS K channels between the two groups. These results indicate mice on LNaHK exhibited furosemide-sensitive net K⁺ secretion in the TAL that is dependent on increased NKCC2 activity and mediated by ROMK. We conclude that furosemide is a K-sparing diuretic by decreasing the TAL net K⁺ secretion in subjects on LNaHK.